Site Map

• Welcome
  • Our Medicines
    • Two-drug, dolutegravir-based regimens 
    • JULUCA
    • CELSENTRI
      • Celsentri Prescribing Information
    • KIVEXA
      • Kivexa Prescribing Information
    • TRIUMEQ
      • Triumeq Prescribing Information
    • TIVICAY
      • Tivicay Prescribing Information
  • Resources
    • Formulary packs
    • Videos
    • Publications
      • SWORD Studies
      • FLAMINGO study (96-week data)
      • VIKING-3 study (24-week data)
      • SPRING-2 study (96-week data)
      • SAILING study (48-week data)
      • SINGLE study (144-week data)
    • Posters
    • HIV Guidelines
  • Therapy Area
    • Grants & Donations
    • ISS
  • News & Events
    • News
      • Glasgow 2018—2-drug regimen
      • Glasgow 2018—Comparable viral decay
      • Glasgow 2018 Comparison of viral replication
      • Glasgow 2018 Comparison of viral replication
      • ARIA at International AIDS Conference 2016
      • STRIIVING at International AIDS Conference 2016
      • ViiV at the 23rd Annual Conference of the British HIV Association
      • IAS 2017—NEAT022 PI/r Switch Lipid Study 48 Week data
      • IAS 2017—DAWNING interim data
      • IAS 2017—OPERA observational database
  • I am a patient
    • I am a Patient taking Juluca (dolutegravir/rilpivirine)
    • I am a patient taking Triumeq (dolutegravir/abacavir/lamivudine)
    • I am a patient taking Tivicay (dolutegravir)
    • I am a patient taking Celsentri (maraviroc)
    • I am a patient taking Kivexa (abacavir/lamivudine)
  • Contact a ViiV Healthcare Advisor
  • Report an Adverse Event
  • Privacy Policy
  • Terms and Conditions
  • Cookie Policy
  • Triumeq and Tivicay combined PI
  • LiVLife
  • Tivicay Epivir and Juluca PI
  • Tivicay Triumeq Juluca PI